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G protein-coupled receptors (GPCRs) are the major class of sensory proteins and a primary therapeutic
target in the pathways to pain and itch. GPCRs are complex signaling machines. Their association with
ligands, other receptors, and signaling and regulatory partners induces GPCRs to adopt distinct conforma-
tions and to traffic to microdomains within plasma and endosomal membranes. This conformational and
positional dynamism controls GPCR signaling in time and space and defines the outcome of receptor acti-
vation. An understanding of the dynamic nature of GPCRs within primary sensory neurons and neighboring
cells brings new insights into their contributions to the physiology and pathophysiology of pain and itch and
provides novel opportunities for therapeutic intervention.1. Introduction
With approximately 850 members, G protein-coupled receptors
(GPCRs) are the largest family of signaling proteins. GPCRs
enable cells to detect structurally diverse agonists, including
most hormones, neurotransmitters, and paracrine agents, as
well as photons, odorants, and tastants. Given the size of this
family, their ubiquitous expression, and the diversity of their
agonists, it is not surprising that GPCRs participate in most
physiological and pathophysiological processes and are a major
target for therapy.
GPCRs are complex signaling machines. Much of this
complexity is due to their conformational and positional
dynamism (Figure 1). All GPCRs comprise seven a-helical trans-
membrane domains, an extracellular N terminuswith three extra-
cellular loops, and an intracellular C terminus with three intracel-
lular loops. GPCRs are not rigid switches that exist in ‘‘off’’
(unbound) and ‘‘on’’ (agonist-bound) conformations. Instead,
they can adopt a series of fleeting conformations that are influ-
enced by association with ligands, other receptors, signaling
and regulatory proteins, by post-translational modifications,
and by environmental cues. This conformational flexibility deter-
mines the capacity of receptors to engage with signaling ma-
chinery. It may explain how ligands that interact with binding
sites that are distinct from those occupied by endogenous
ligands can alter receptor function (allosteric modulation,
Figure 1A), and how different ligands of the same receptor can
preferentially activate certain signaling pathways (signaling
bias, Figure 1B). Changes in conformation are also likely to
determine how interactions between two different receptor mol-
ecules can influence their function (receptor oligomerization,
Figure 1C) and account for the ability of certain GPCRs to
become active in the absence of ligand (constitutive activity,
Figure 1D). The dynamic nature of GPCRs is further illustrated
by the trafficking of activated receptors from the cell surface tothe endosomal network. Agonist-stimulated trafficking enables
GPCRs to assemble signaling complexes in subcellular com-
partments, which can lead to unique downstream outcomes
(compartmentalized signaling) (Figure 1E). Variants of receptors
that are produced by alternate mRNA splicing exhibit altered
conformation and trafficking, which adds further complexity.
GPCRs are the largest class of sensory proteins and are impor-
tant therapeutic targets in thepathways topain and itch (Figure2).
Pseudounipolar primary sensory neurons of dorsal root, trigemi-
nal, and vagal ganglia, also known as nociceptors and prurito-
ceptors, are the first cells in these pathways. The peripheral end-
ings of these neurons are equipped with GPCRs that sense
structurally diverse stimulants and inhibitors of neuronal activity.
Second-order spinal neurons also express GPCRs for transmit-
ters released from thecentral endingsof primary sensoryneurons
and from other spinal neurons. Second-order neurons integrate
signals and transmit pain and itch to the brain. During disease,
there are remarkable changes in the levels and types of GPCRs
that are expressed by primary sensory neurons and their targets,
which further illustrates the dynamic nature of this system.
Herein, we discuss the conformational and positional dyna-
mism of GPCRs that control pain and itch. We highlight the
importance of allosteric modulation, biased agonism, receptor
oligomerization, constitutive activity, and trafficking-dependent
signaling for pain and itch transmission, and therapeutic inter-
vention. We illustrate these processes by discussing selected
GPCRs of primary sensory and spinal neurons. We refer readers
to comprehensive reviews of the mechanisms of pain and itch
(Basbaum et al., 2009; Bautista et al., 2014).
2. GPCRs of the Pathways to Pain and Itch
2.1. GPCRs of Primary Sensory Neurons
GPCRsenable sensory nerves to detect structurally diverse stim-
ulants and inhibitors, including amines (histamine, serotonin),Neuron 88, November 18, 2015 ª2015 Elsevier Inc. 635
Figure 1. GPCR Signaling and Trafficking
(A) Allosteric modulators. Orthosteric ligands
(gray) bind and stimulate signaling. Allosteric
modulators bind to distinct sites and influence
signaling. PAMs (blue) enhance signaling,
whereas NAMs (red) have the opposite effect.
(B) Signaling bias. Ligands 1 and 2 stabilize
distinct GPCR conformations that activate
different pathways (A and B).
(C) Oligomerization. Ligand binding to one
monomer (GPCR-A) can induce conformational
changes in the other monomer (GPCR-B) that
mediate signaling (pathway B).
(D) Constitutive signaling. In the absence of ago-
nists, GPCRs can engage signaling partners.
(E) Compartmentalized signaling. Ligand binding
at the plasma membrane activates pathway A.
Internalized GPCRs assemble signalosomes that
activate pathway B.
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Reviewpeptides (kinins, tachykinins, opioids), purines and nucleotides
(adenosine, ATP), lipids (prostaglandins), steroids (bile acids),
and proteases (serine and cysteine) (Figure 2A).
Histamine and 5-hydroxytryptamine (5-HT) are prominent stim-
ulants of pain and itch. In common with many agonists, histamine
and 5-HT can activate several receptor subtypes, sometimeswith
different outcomes. Histamine causes pain and itch by activating
histamine 1 receptors (H1R) on cutaneous afferent nerves (Rosa
andFantozzi, 2013). 5-HTenhancesexcitability ofprimarysensory
nerves to evoke hyperalgesia and scratching by activating
5-HT2BRand5-HT7R (Cardenaset al., 1999;Lin etal., 2011;Morita
et al., 2015). However, activation of the inhibitory Gai-linked H3R
suppresses the release of sensory neuropeptides and dampens
pain transmission (Geppetti et al., 2012; Hough and Rice, 2011).
Bradykinin, generated during injury and inflammation by the
action of kallikreins on kininogens, is the prototype algesic
peptide of inflammatory exudates. Bradykinin induces acute
nociceptive behavior by activating the B2R on sensory nerves,
whereas the B1R plays a more prominent role during persistent636 Neuron 88, November 18, 2015 ª2015 Elsevier Inc.pain (Peth}o and Reeh, 2012). The m, d,
and k opioid receptors (MOR, DOR, and
KOR) are the most extensively studied
antinociceptive GPCRs and a therapeutic
target for pain. DOR and MOR are
expressed by primary sensory neurons
where activation inhibits hypersensitivity
(Scherrer et al., 2009). DOR is expressed
by cutaneous mechanoreceptors, and
DOR activation on the central terminals
of mechanoreceptors suppresses synap-
tic input to the dorsal horn, suggesting
that DOR is a target for injury-evokedme-
chanical hypersensitivity (Bardoni et al.,
2014). During inflammation opioids from
immune cells can activate ORs of primary
sensory nerves and may thereby inhibit
inflammatory pain (Boue´ et al., 2014).
Injury and inflammation result in the
activation of a large number of serine
and cysteine proteases that derive fromthe circulation (coagulation factors), immune cells (mast cell
tryptase, macrophage cathepsin S, neutrophil elastase), and
epithelial tissues (trypsin IV, kallikreins). These proteases can
regulate primary sensory nerves by cleaving protease-activated
receptor-2 (PAR2). PAR2 agonists excite or sensitize sensory
neurons to promote neurogenic inflammation (Steinhoff et al.,
2000), pain (Vergnolle et al., 2001), and itch (Reddy et al.,
2008; Steinhoff et al., 2003).
Membersof the large family ofMas-relatedGPCRs (Mrgprs) are
expressed by primary sensory neurons and are important media-
tors of pain and itch (Donget al., 2001). The antimalarial drug chlo-
roquine, which causes severe itch that can limit compliance, in-
duces MrgprA3-dependent scratching in mice (Liu et al., 2009).
Bovineadrenalmedullapeptide8-22 (BAM8-22), aproductofpro-
enkephalin A, activatesMrgrpC11 inmice to induce itch (Liu et al.,
2009). Mice lacking a cluster of Mrgprs genes, notably MrgprA3
and MrgprC11, display exaggerated inflammatory hyperalgesia
yet normal neuropathic hypersensitivity, indicating that certain
Mrgprs can inhibit inflammatory pain (Guan et al., 2010).
Figure 2. GPCR Mediation of Pain, Itch, and Neurogenic Inflammation
(A) Sensation. GPCRs on the peripheral terminals of primary spinal afferent neurons sense stimulants and inhibitors of neuronal activity from immune cells, the
circulation, and epithelial tissues.
(B) Neurogenic inflammation. The peripheral terminals of primary sensory neurons release SP, which activates the NK1R on endothelial cells of postcapillary
venules to cause plasma extravasation and granulocyte infiltration and on epithelial cells to stimulate cytokine release. SP also activatesMrgprB2 onmast cells to
induce degranulation (McNeil et al., 2015). CGRP activates calcitonin receptor-like receptor and receptor activity modifying protein 1 (CLR/RAMP1) on arterioles
to cause vasodilation and hyperemia.
(C) Central transmission. Central terminals of primary sensory neurons release glutamate, SP, and CGRP, which activate their GPCRs on spinal neurons to
promote central transmission.
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Prominent transmitters released from the central projections of
primary spinal afferent neurons include glutamate, substance
P (SP), and calcitonin gene-related peptide (CGRP), which acti-
vate GPCRs of dorsal spinal neurons (Figure 2B). For example,
noxious peripheral stimuli trigger SP release in the dorsal horn
and subsequent activation and endocytosis of the neurokinin 1
receptor (NK1R) (Mantyh et al., 1995). Neuropeptides from
intrinsic neurons, including the analgesic opioids, can also regu-
late the activity of second order spinal neurons that transmit pain
and itch. Gastrin-releasing peptide (GRP), the mammalian ho-
molog of the amphibian skin peptide bombesin, is an itch-selec-
tive transmitter in the spinal cord (Sun and Chen, 2007). There
has been considerable controversy about whether GRP origi-
nates from primary sensory or spinal neurons, although studies
using in situ hybridization, immunofluorescence, and a
GRPeGFP reporter mouse suggest that spinal interneurons are
the primary source (Solorzano et al., 2015). Whereas GRP
released within the spinal cord can activate spinal neurons ex-pressing the GRP receptor to evoke itch, dynorphin, which
derives from a population of spinal inhibitory interneurons, acti-
vates KOR within the spinal cord to suppress itch (Kardon
et al., 2014).
3. The GPCR-TRP Channel Axis: Partners on the
Pathways to Pain and Itch
The capacity of GPCRs to excite primary sensory neurons re-
quires activation of transient receptor potential (TRP) ion chan-
nels (Figure 3). Although the 28 member TRP family is dwarfed
by the GPCR superfamily, the activities of many GPCRs
converge on a small number of TRP channels, which are vitally
important for sensory signaling (reviewed in Veldhuis et al.,
2015). Members of the TRP vanilloid (TRPV1, TRPV2, TRPV3,
TRPV4), TRP melastatin (TRPM2, TRPM8), and TRP ankyrin
(TRPA1) subfamilies are downstream effectors of GPCR noci-
ceptive and pruritogenic signaling.
TRPs are non-selective cation channels of four identical or
similar subunits, each with six transmembrane domains andNeuron 88, November 18, 2015 ª2015 Elsevier Inc. 637
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Figure 3. The GPCR-TRP Axis
GPCRs activate multiple pathways that converge
on TRP channels. Gaq protein signaling (green)
stimulates PLA2 to produce arachidonic acid (AA)
and downstream polyunsaturated fatty acid
(PUFA) endogenous TRP channel ligands via LOX,
cytochrome P450, and COX activity. PLC metab-
olizes PIP2 to produce DAG, IP3, and intracellular
Ca2+ release, increasing PKC kinase activity
and TRP channel phosphorylation. Gas protein
signaling (red) stimulates adenylate cyclase (AC)
activity; cAMP production and PKA activity pro-
mote TRP channel phosphorylation and sensitiza-
tion. Together, these pathways increase the likeli-
hood of TRP channels responding to endogenous
stimuli. Conversely, Gai/o signaling (purple) pro-
motes analgesia through inhibition of AC-depen-
dent cAMP formation. Gbg proteins (blue) activate
TRPA1 and cause itch through pathways that are
yet to be characterized in detail. TRP channel ac-
tivity stimulates voltage-gated ion flux, membrane
depolarization and downstream action potentials
(AP) for central transmission of pain or itch. Stim-
ulated primary afferent terminals also release
peptides in the periphery (e.g., SP, CGRP) to
mediate itch and neurogenic inflammation.
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lular pore domains are sensitive to environmental cues, including
temperature and pH (TRPV1), mechanical stimuli (TRPV4), reac-
tive oxygen species (TRPA1), and direct stimulation by natural
products, such as capsaicin from chilies (TRPV1), allyl isothio-
cyanate from horseradish (TRPA1), and menthol from mint
(TRPM8). In addition to these direct mechanisms of activation,
the membrane-spanning and intracellular regions of TRPs can
undergo post-translational modification and bind to signaling
messengers, which both mediate GPCR-stimulated channel
activity. The concept that TRPs are ‘‘receptor-operated
channels’’ was originally observed in Drosophila melanogaster,
where TRP mutants displayed diminished responses to the
GPCR rhodopsin (Hardie and Raghu, 2001).
3.1. Mechanistic Basis of the GPCR-TRP Axis
GPCRs can stimulate TRPs by two general mechanisms:
Ga-mediated activation of phospholipases (e.g., PLCb, PLA2)
that relieve phosphatidylinositol 4,5-bisphosphate (PIP2)-depen-
dent channel inhibition and generate endogenous TRP agonists,
and stimulation of kinases (protein kinase (PK)C, PKA, tyrosine
kinases) that phosphorylate TRPs to increase cell-surface
expression and interactions with adaptor proteins (Veldhuis
et al., 2015) (Figure 3). These mechanisms lead to TRP channel
sensitization (i.e., increase TRP sensitivity to non-noxious stim-
uli) or activation.
3.2. The GPCR-TRP Pathway to Pain and Itch
In primary sensory nerves, GPCRs can stimulate TRP-mediated
cation influx, which activates voltage-operated Na+ channels
that mediate depolarization and central transmission. For
example, TRPV1, TRPV4, and TRPA1 mediate the nociceptive
actions of GPCRs for proteases (PAR2), bradykinin (B1R, B2R),
prostaglandins (EP, IP receptors), ATP (P2Y1,2,11), histamine
(H1R, H2R), and serotonin (5HT1, 5HT4) (Veldhuis et al., 2015).
The GPCR-TRP axis also contributes to itch. Whereas TRPV1
is implicated in histamine-dependent itch, TRPA1 mediates his-
tamine-independent itch (Bautista et al., 2014). Histamine/H1R638 Neuron 88, November 18, 2015 ª2015 Elsevier Inc.activate TRPV1 in sensory nerves by PLC/PKC- and PLA2/lipox-
ygenase-pathways, leading to scratching in mice (Kim et al.,
2004; Shim et al., 2007). Several pruritogenic GPCRs cause
TRPA1-dependent excitation of sensory nerves and scratching
in mice, albeit by divergent signaling mechanisms. Whereas
the pruritogenic actions of chloroquine involve MrgprA3- and
Gbg-dependent activation of TRPA1, the effects of Bam8-22
involve MrgC11- and PLCb-dependent activation of TRPA1
(Wilson et al., 2011, 2013a). The bile acid receptor TGR5 is a po-
tential mediator of pruritus in patients with cholestatic liver dis-
ease and increased circulating levels of bile acids (Alemi et al.,
2013). TGR5 induces Gbg- and PKC-mediated activation of
TRPA1 in cutaneous afferent neurons, leading to release of the
pruritogenic neuropeptides GRP and natriuretic polypeptide B,
activation of spinal neurons, and scratching (Lieu et al., 2014).
Sequestration of bile acids and antagonism of TRPA1 ameliorate
spontaneous scratching in Tgr5 transgenic mice, which sug-
gests TGR5-mediated activation of TRPA1 is pathophysiologi-
cally important.
Proteases that activate PAR2 can evoke a TRPA1-dependent
itch in mice by a complex mechanism that involves keratino-
cytes, immune cells, and sensory nerves. Proteases that activate
PAR2 in the epidermis stimulate the production of itch-inducing
cytokines, including thymic stromal lymphopoietin (TSLP), from
keratinocytes (Moniaga et al., 2013). TLSP, a chemoattractant
for immune cells, activates TLSP chemokine receptor signaling
and TRPA1 activity on sensory neurons to induce scratching
(Wilson et al., 2013b). Mediators released from epithelial cells
in multiple tissues may similarly activate sensory nerves to
induce pain and itch.
4. AllostericModulators of GPCRs: Pathways to Subtlety
Allostery, from the Greek for other (allos) site (stereos), refers to
the capacity of a ligand to interact with a protein at a site that
is distinct from the binding site for endogenous ligands or sub-
strates. Allosteric modulators alter the conformation of proteins
Neuron
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or inhibit (negative allosteric modulators [NAMs]) their activities.
Signaling and regulatory proteins, including G proteins, that
interact with GPCRs are physiological allosteric modulators. In
addition, certain drugs can interact with allosteric sites of GPCRs
(reviewed in Wootten et al., 2013) (Figure 1A). Allosteric drugs
offer increased opportunity for receptor subtype selectivity,
since allosteric sites are less likely than orthosteric sites to be
conserved between GPCR subtypes. By modulating responses
to endogenous agonists, allosteric drugs may allow ‘‘fine-tun-
ing’’ of regulatory processes. However, little is known about
the structural basis of allosteric modulation of GPCRs, which
hinders rational drug design, although recent advances in
GPCR structural biology are beginning to address this issue.
Moreover, allosteric drugs can be species specific, due to the
lack of evolutionary pressure to conserve allosteric sites. There
are currently two approved allosteric modulators of GPCRs
(cinacalcet, a calcium-sensing receptor PAM for hyperparathy-
roidism; maraviroc, a chemokine receptor 5 NAM for HIV).
Although both drugs were found to be allosteric modulators ex
post facto, there remains a sustained interest in developing allo-
steric modulators of GPCRs for pain (Nickols and Conn, 2014).
4.1. Structural Basis of Allosteric Modulation
Structural studies of family A (rhodopsin-like) GPCRs show that
transmembrane and extracellular domains accommodate or-
thosteric ligands. Little is known about the structural basis of
allosteric modulation of GPCRs. A notable exception is the
b2-adrenergic receptor (b2AR), where G protein association pro-
motes high-affinity binding of an orthosteric ligand (Rasmussen
et al., 2011). Here, a network of conformational changes connect
the orthosteric ligand binding site and the allosteric G protein
binding site at the intracellular face of the receptor. Observations
of the muscarinic M2 receptor bound to an orthosteric agonist
and a small molecule PAM indicate the presence of an extracel-
lular vestibule for allosteric modulators that is pre-formed in the
presence of agonist (Kruse et al., 2013).
4.2. PAMs for Pain
The identification of allosteric drugs that amplify the anti-noci-
ceptive effects of GPCR ligands is an attractive strategy for
‘‘dialing down’’ pain. A rationale for developing such drugs is
that the usefulness of orthosteric agonists is often limited by
side effects, and PAMs that amplify or bias the actions of endog-
enous ligands may allow for more subtle control. For example,
MORPAMswould be expected to enhance the analgesic activity
of endogenous opioids or MOR agonists. However, since MOR
mediates the beneficial analgesic actions of opioids, as well as
the detrimental effects of dependence, respiratory depression,
and constipation, there is no a priori reason why PAMs would
be expected to have an improved therapeutic profile unless
there is also an element of bias in their allosteric effects (Kenakin
and Christopoulos, 2013). MOR PAMs have been identified that
enhance b-arrestin recruitment and cAMP inhibition induced by
the orthosteric agonist endomorphin-I (Burford et al., 2013).
Their effects may be related to interference with the interaction
between MOR and Na+ ions, endogenous NAMs that stabilize
inactive receptors (Livingston and Traynor, 2014). PAMs for me-
tabotropic gamma-amino-n-butyric acid (GABA)B receptors are
also attractive given the anti-nociceptive actions of these recep-tors in chronic but not acute pain (Hanack et al., 2015). Studies
of selectivity and efficacy in preclinical models are required to
determine whether PAMs of analgesic GPCRs are useful treat-
ments for pain.
4.3. NAMs for Pain
NAMs that attenuate the activation of pro-nociceptive GPCRs by
endogenous agonists offer the possibility of more subtle sup-
pression of pain than could be achieved by competitive inhibi-
tors. The rational design of a small molecule allosteric inhibitor
of the C5a receptor (C5aR) illustrates the potential of this
approach (Moriconi et al., 2014). C5a, an anaphylatoxin peptide
generated during complement activation, signals to the C5aR on
primary sensory neurons, spinal microglial cells, and immune
cells to induce inflammatory and neuropathic pain. Although
C5aR is an attractive target, orthosteric antagonists lack selec-
tivity and potency, or have poor bioavailability and short half-
life (Griffin et al., 2007; Moriconi et al., 2014). A selective and
non-competitive allosteric inhibitor of C5aR suppresses me-
chanical hyperalgesia in acute and chronic models of inflamma-
tory and neuropathic pain in mice, yet lacks anti-nociceptive
activity in C5aR knockout mice, which confirms specificity.
5. The Janus Face of GPCRs: Pathways to Biased
Agonism
In a manner that is reminiscent of Janus, the Roman god of
transitions, GPCRs translate extracellular cues into intracellular
signals. A common feature of GPCRs is the existence of several
ligands of the same receptor. Based on the assumption that ag-
onists would all stabilize a single active conformation of the re-
ceptor, the prevailing view was that individual GPCRs would
activate the same signaling events. However, it is now clear
that different agonists can selectively stabilize unique conforma-
tions that favor receptor coupling to particular signaling path-
ways (i.e., biased agonism, reviewed in Kenakin and Christo-
poulos, 2013) (Figure 1B). Thus, like Janus, a god with two
faces, GPCRs can adopt distinct conformations that dictate their
activation of various signaling pathways. Biased agonism may
allow different endogenous agonists of the same receptor to
exert distinct physiological effects, although this possibility has
not been thoroughly evaluated. Biased agonism also holds the
tantalizing prospect of developing ‘‘designer agonists’’ that
would be biased toward the activation of therapeutically benefi-
cial pathways at the expense of those that underlie detrimental
side effects.
There are formidable challenges in understanding the impor-
tance of biased agonism, particularly in vivo (reviewed in Zhou
andBohn, 2014). An understanding of the relevance of biased ag-
onism is hampered by the paucity of information about the
signaling events that underlie the actions of endogenous agonists
anddrugs. The attribution of different actions of agonists in vivo to
biased agonism is fraught with problems. Differences in themeta-
bolic stability, tissue penetrance, duration of association with re-
ceptors, rather than biased agonism, may all explain differential
effects of agonists. Off-target effects of agonists or their metabo-
litesonotherGPCRsorunrelatedproteinsmayalsogive rise to the
artifactual appearance of biased agonism. Although the capacity
of different agonists to stabilize unique receptor conformations is
thought to underlie biased agonism, such information exists forNeuron 88, November 18, 2015 ª2015 Elsevier Inc. 639
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tween ligands and receptors may also account for apparent
biased agonism (reviewed in Hoffmann et al., 2015).
5.1. Structural Basis of Biased Agonism
Structural studies of GPCRs are beginning to provide insights
into biased signaling. The ability of agonists to differentially regu-
late b2AR signaling depends on their capacity to influence
the conformation of helix VI for G protein bias or helix VII for
b-arrestin bias (Liu et al., 2012). Studies of the b2AR bound to
b-arrestin-biased ligands provide further insight (Warne et al.,
2012). Ergotamine, a treatment for migraine pain and a precursor
of the hallucinogen lysergic acid, is a biased agonist of b-arrestin
signaling of the 5-HT2BR (hallucinogen action) but is an unbiased
agonist of the 5-HT1BR (antimigraine action) (Wacker et al.,
2013). Given the emerging importance of b-arrestin in mediating
the therapeutic and adverse actions of certain drugs, such struc-
tural insights may be important for drug development.
5.2. Biased Agonism of Opioid Receptors
AlthoughMORagonists, such asmorphine, oxycodone, and fen-
tanyl, are widely used analgesics, their usefulness is limited by
analgesic tolerance and side effects. Is it possible that different
signaling pathways underlie the beneficial and detrimental ac-
tions of MOR, and could ‘‘designer analgesics’’ favor the benefi-
cial over the detrimental pathways? This prospect has generated
numerous studies of MOR signaling and trafficking and of the
relevance of biased agonism for analgesia, tolerance, and side
effects (reviewed in Williams et al., 2013).
Studies of b-arrestin-2-deficient mice have revealed differen-
tial roles of b-arrestin-2 in analgesia, tolerance, and the side ef-
fects of MOR agonists. Whereas b-arrestin-2 inhibits anti-noci-
ceptive signaling of MOR (Bohn et al., 1999), it mediates MOR
signaling that underlies the unwanted side effects of morphine
(Raehal et al., 2005). These findings provided the impetus to
seek MOR agonists that display biased signaling toward G pro-
tein pathways thatmediate analgesia and away from b-arrestin-2
signaling pathways that are responsible for side effects. TRV130
is a synthetic MOR agonist with G protein-coupling efficacy
similar to morphine and DAMGO, yet with reduced efficacy for
b-arrestin-2 recruitment (DeWire et al., 2013). Consistent with
its reduced ability to recruit b-arrestin-2, TRV130 minimally
stimulates MOR phosphorylation or internalization and retains
analgesic activity in rodents, with reduced constipation and res-
piratory depression. In healthy men, TRV130 produced greater
analgesia than morphine with a smaller reduction in respiratory
drive and less nausea (Soergel et al., 2014).
An alternative to using biased agonists of MOR to improve
pain treatment has been to target MOR variants. The MOR
gene Oprm1 generates multiple splice variants, some of which
encode a version of MOR with 6 transmembrane domains
(mMOR-1G). 3-iodobenzoyl-6b-naltrexamide causes mMOR-
1G-dependent analgesia in mice, without the side effects of res-
piratory depression and dependence (Lu et al., 2015). Although
mMOR-1G may be a viable therapeutic target, further studies
are required to define the importance of GPCR variants in pain
and itch.
5.3. Biased Agonism of Protease-Activated Receptors
Whereas the functional selectivity of most agonists results from
reversible receptor binding, biased agonism of PARs arises640 Neuron 88, November 18, 2015 ª2015 Elsevier Inc.from irreversible proteolysis, which leads to distinctly different
pathways of receptor signaling and trafficking and divergent
mechanisms of pain (reviewed in Zhao et al., 2014b) (Figure 4).
Trypsin, tryptase, and kallikrein cleave PAR2 at the canonical
R36YS37 site, which exposes a tethered ligand that binds and
activates the cleaved receptor. Trypsin-cleaved PAR2 couples
to Gaq/11, second messenger kinases, and b-arrestins (Amadesi
et al., 2006; Ayoub and Pin, 2013; DeFea et al., 2000b). PAR2
sensitizes TRPV1 (Amadesi et al., 2004), TRPV4 (Poole et al.,
2013), and TRPA1 (Dai et al., 2007) by mechanisms that include
channel phosphorylation, synthesis of endogenous agonists,
and release of PIP2-mediated inhibition. In contrast, cathepsin
S (from macrophages, spinal microglial cells) and elastase
(neutrophils, leukocytes) cleave PAR2 at distinct sites, leading
to divergent pathways of receptor signaling, trafficking, and
TRP channel activation (Zhao et al., 2014a, 2015). Thus, PAR2
can integrate the actions of diverse proteases. The report that
cathepsin S can also activate MrgprC11 to cause itch adds to
the complexity of protease signaling to sensory nerves (Reddy
et al., 2015).
6. Oligomerization of GPCRs: Pathways to Diversity
Many receptors, including receptor tyrosine kinases and toll-like
receptors, function as oligomers. The assembly of homodimers
(2 identical receptors), heterodimers (2 different receptors), or
multimers (>2 receptors) can influence ligand recognition, acti-
vation, signal transduction, and trafficking of these receptors
and is thus essential for their normal function (Figure 1C).
Whether GPCRs also interact with one another has been a topic
of interest and controversy (reviewed in Ferre´ et al., 2014). This
controversy has led to the adoption of stringent criteria that are
necessary to establish the existence of GPCR oligomerization.
They include the demonstration that both receptors physically
associate in native tissues or primary cells, identification of a
key functional property of the receptor oligomer, and studies of
animals in which one component of the complex is deleted or
downregulated (Pin et al., 2007). If GPCR dimers are to be
considered therapeutic targets, it is also important to study
colocalization and dimerization in diseased states, where the
patterns of expression and subcellular localization of receptors
can be markedly altered.
6.1. Oligomerization of Family C GPCRs
The strongest evidence for GPCR dimerization comes from the
family C GPCRs, which include receptors for excitatory (gluta-
mate) and inhibitory (GABA) neurotransmitters of pain pathways.
Family C GPCRs possess a large extracellular N terminus, which
contains multiple cysteine residues and a ligand binding Venus
flytrap domain. Disulphide linkage between extracellular do-
mains stabilize homodimers of metabotropic glutamate recep-
tors (mGluRs) (Romano et al., 1996). Dimerization allosterically
couples the Venus flytrap and heptahelical domains and is
necessary for ligand binding and G protein coupling (Tsuchiya
et al., 2002). Homodimerization of mGluRs is likely to be neces-
sary for pain transmission. mGluR1 and mGluR5 are expressed
by primary sensory neurons and spinal neurons, and antagonists
of these receptors suppress pain (Goudet et al., 2009). Heterodi-
merization of GABAB1 and GABAB2 receptors masks an endo-
plasmic retention motif of the GABAB1 subunit and thereby
Figure 4. Protease-Biased Agonism of
PAR2
(A) Trypsin/tryptase, cathepsin S, and elastase
cleave within the extracellular N terminus of PAR2
at distinct sites. Exposed tethered ligands are
shown in red (trypsin/tryptase) and blue (cathepsin
S). Elastase does not activate PAR2 by a tethered
ligand mechanism.
(B) Canonical and biased mechanisms of protease
signaling. Trypsin/tryptase-activated PAR2 cou-
ples predominantly to Gaq11 and b-arrestin.
Cathepsin S- and elastase-activated PAR2 cou-
ples to Gas and adenylyl cyclase (AC) or Ga12/13
and Rho kinase.
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2000). Agonist binding to the GABAB1 component allosterically
activates GABAB2, which mediates signal transduction (Galvez
et al., 2001). GABAB1 knockout mice fail to respond to exoge-
nous GABAB agonists and exhibit hyperalgesia due to absence
of the normal tonic inhibitory activity of GABA in the dorsal
horn, which illustrates the importance of this component of the
dimer for normal receptor functions (Schuler et al., 2001). The
relevance of GABAB dimerization for pain is illustrated by
the finding that disruption of dimerization, by negating the tonic
inhibitory actions of GABA in the dorsal horn, exacerbates pain
(Laffray et al., 2012).
6.2. Opioid Receptor Homo- and Hetero-dimers
Studies of single monomers of detergent-solubilized MOR re-
constituted with Gai2 in lipid vesicles show that this receptor
can function as a monomer but do not exclude the possibility
that it also functions as an oligomer (Kuszak et al., 2009). Indeed,
MOR in complex with the antagonist b-funaltreaxamine crystal-
lizes as a symmetrical dimer (Manglik et al., 2012). A dimeric
interface has also been identified from structural studies of
KOR bound to the antagonist JDTic (Wu et al., 2012). In contrast,
a similar dimeric interface was not observed in crystals of DORNeuron 88, Nbound to the antagonist naltrindole (Gra-
nier et al., 2012). It remains to be seen
whether agonist-occupied ORs crystalize
as dimers.
There are widespread reports of MOR-
DOR heterodimers in cell lines and native
tissues, where heteromers may facilitate
signaling (Gomes et al., 2004; Gupta
et al., 2010). However, a prerequisite for
dimerization is that MOR and DOR are
colocalized not only in the same neuron
but also within the same membrane
microdomains. In some cases, this infor-
mation is lacking or controversial. The
association of these receptors has been
questioned by the report that immunore-
active MOR and DOR-eGFP are largely
expressed by different populations of
peptidergic (MOR) and non-peptidergic
(DOR) neurons of mouse dorsal root
ganglia that separately control thermal
(MOR) and mechanical (DOR) nocicep-tion (Scherrer et al., 2009). Although a subsequent study of
DOR-eGFP and MOR-mCherry double knockin mice found
that a more substantial proportion of neurons coexpress these
receptors (Erbs et al., 2015), these results are at odds with other
reports showing extensive overlap (Wang et al., 2010). Different
methodologies may account for reported variability in the coex-
pression of these (and other) GPCRs.
After chronic use, the analgesic actions of morphine and fen-
tanyl, which are mediated by MOR, are limited by tolerance. The
MOR-DOR heteromer has been proposed to mediate analgesia
and tolerance and to represent a target for analgesics with
reduced tolerance. DOR disruption can enhance MOR-depen-
dent analgesia and diminish tolerance, which suggests that
DOR suppresses MOR activity and mediates tolerance (Zhu
et al., 1999). This inhibitory action of DORmay be related to alter-
ations in post-endocytic sorting of MOR-DOR heteromers. Once
internalized, MOR recycles and DOR traffics to lysosomes. How-
ever, DOR agonists promote internalization and degradation
of both components of the MOR-DOR heteromer, which could
diminish cell-surface MOR expression and contribute to toler-
ance (He et al., 2011). Peptides that interfere with assembly
of heteromers enhance morphine analgesia and attenuateovember 18, 2015 ª2015 Elsevier Inc. 641
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on the MOR agonist oxymorphone and the DOR antagonist nal-
trindole linked by spacer have anti-nociceptive activity and
diminished tolerance (Daniels et al., 2005). Only those ligands
with an appropriate spacer length did not produce tolerance,
which supports the view that they target the MOR-DOR hetero-
mer. The therapeutic utility of bifunctional drugs is illustrated by
finding that Eluxadoline, a molecule with MOR agonist and DOR
antagonist activity, relieves abdominal pain in patients with diar-
rhea-predominant irritable bowel syndrome (Dove et al., 2013).
Eluxadoline is now approved for treatment of diarrhea-predom-
inant irritable bowel syndrome. Recent structural studies of ORs
in complex with such bivalent drugs may facilitate the rational
design of improved analgesics (Fenalti et al., 2015).
6.3. Heterodimerization of Opioid Receptors with Other
GPCRs
Although the intrathecal administration of morphine is an effec-
tive treatment for severe pain that can restrict some of the side
effects of systemic administration, its usefulness is often limited
by severe pruritus. Studies in mice suggest that a heterodimer of
a splice variant of MOR, MOR1D, and the GRP receptor mediate
morphine-induced scratching, whereas theMOR1 formof the re-
ceptor mediates morphine-induced analgesia (Liu et al., 2011).
Peptides that disrupt assembly of the MOR1D/GRP receptor
dimer inhibit morphine-induced scratching but not analgesia.
These findings suggest that agonists of MOR1 that are unable
to activate the MOR1D/GRP receptor heterodimer may achieve
effective analgesia without the side effects of pruritus. A 5-HT1R/
GRP receptor heterodimer similarly facilitates itch transmission
in the spinal cord (Zhao et al., 2014c).
7. Constitutively Active GPCRs: Pathways to
Agonist-Independent Pain and Itch
Given their dynamic nature, it is not surprising that GPCRs can
spontaneously adopt active conformations even in the absence
of agonists (reviewed in Smit et al., 2007) (Figure 1D). This consti-
tutive activity increases basal cellular signaling and is sensitive to
inhibition by inverse agonists. Inverse agonists have the oppo-
site effects of agonists: whereas agonists activate receptors,
inverse agonists inhibit their constitutive activity. One of the
earliest descriptions of constitutive activity of GPCRs was the
identification of inverse agonists of DOR that inhibited basal
GTPase activity of neuroblastoma cells expressing wild-type
DOR (Costa and Herz, 1989). It is now clear that many, if not
all, GPCRs can demonstrate constitutive activity and that this ac-
tivity can be enhanced by receptor mutation or overexpression
of G proteins. However, most information about constitutive ac-
tivity of GPCRs derives from studies of overexpressed receptors
in model cell systems. Far less is known about the importance of
agonist-independent GPCR signaling for physiological control
and mechanisms of disease.
7.1. Structural Basis of Constitutive Activity
Studies of mutant GPCRs and homology models have facilitated
the identification of multiple domains that may contribute to
constitutive activity, particularly in transmembrane regions.
However, with the exception of rhodopsin, little is known about
the structural basis of constitutive activity, in large part due to
the problems associated with crystallizing GPCRs in an acti-642 Neuron 88, November 18, 2015 ª2015 Elsevier Inc.vated state. Crystal structures are available for many forms of
rhodopsin, including constitutively active forms, and have pro-
vided important insights to agonist-induced and constitutive
activity (reviewed in Park, 2014). The constitutive activity of
naturally occurring mutants of rhodopsin may underlie vision
disorders.
7.2. Constitutive Activity and Pain
Although wild-type and mutants of MOR demonstrate constitu-
tive activity, one of the most intriguing findings is that long-
term exposure to agonists, such as morphine, can induce a
constitutively active form of MOR in cell lines and in vivo (Connor
and Traynor, 2010). Constitutive activity of MOR has been pro-
posed to mediate sustained analgesia by endogenous opioids
and to contribute to dependence (Corder et al., 2013). Intraplan-
tar injection of complete Freund’s adjuvant leads to sustained
hyperalgesia in mice that resolves over days. This resolution is
reversed by centrally acting MOR antagonists and is thus medi-
ated by the central actions of endogenous opioids. The develop-
ment of analgesia coincides with constitutive activation of MOR
within the spinal cord, and intrathecal administration of inverse
MOR agonists reinstates the central sensitization of pain and in-
duces signs of opioid withdrawal. Thus, constitutive activity of
spinal MORmay contribute to both analgesic signaling of endog-
enous opioids and the development of tolerance. Although
molecular mechanisms responsible for agonist-stimulated
constitutive activity of MOR remain to be fully defined, constitu-
tive activity may reflect altered phosphorylation of the activated
receptor. However, other mechanisms, such as b-arrestin-2
deficiency, may also contribute to constitutive activity (Walwyn
et al., 2007). Further studies are required to define the molecular
and structural basis of GPCR constitutive activity and to
determine its importance in the control of physiological and
chronic pain.
8. Compartmentalized Trafficking and Signaling of
GPCRs: Pathways to Selectivity
Agonist-evoked endocytosis is a striking demonstration of the
dynamic nature of GPCRs. This positional dynamism allows re-
ceptors to associate with signaling partners and assemble sig-
nalosomes that generate signals in subcellular compartments
(reviewed in Irannejad and von Zastrow, 2014; Murphy et al.,
2009) (Figure 1E). Trafficking-dependent compartmentalized
signaling may explain how different receptors that couple to
the same signaling pathways can selectively control cellular pro-
cesses. It may also mediate pathological processes and could
be a relevant therapeutic target. The inability of antagonists to
effectively engage with GPCRs in subcellular compartments,
which requires that they traverse several membrane barriers
and interact with receptors within multi-protein complexes in
acidified endosomes, may sometimes account for their lack of
efficacy.
8.1. Plasma Membrane Signaling is Tightly Controlled
Ligand degradation/reuptake and receptor desensitization/endo-
cytosis control plasmamembraneGPCR signaling (Figure 5, step
1). Cell-surface peptidases that degrade neuropeptides can
terminate their biological effects (Figure 5, step 1). Neprilysin
(EC 3.4.24.11) degrades SP, bradykinin, and enkephalins in the
extracellular fluid, and mice lacking neprilysin show widespread
Figure 5. Trafficking and Signaling of the
NK1R
(1) Desensitization. Neprilysin (NEP) degrades
extracellular SP and restricts NK1R activation.
GRKs (2,3,5) phosphorylate the NK1R, which in-
teracts with b-arrestins and desensitizes. Protein
phosphatase PP2A reverses this phosphorylation
to resensitize non-internalized NK1R. (2) Endocy-
tosis. b-arrestins couple the NK1R to clathrin and
AP2 to mediate endocytosis to rab5a-positive
early endosomes. (3) Endosomal signaling. b-ar-
restins recruit the NK1R, Src, MEKK, and ERK1/2
to endosomes and thereby assemble signal-
osomes that allow the endocytosed NK1R to
continue to signal. (4) Fast recycling. The NK1R
can rapidly recycle from superficially located en-
dosomes by rab4a- and rab11a-dependent pro-
cesses. (5) Post-endocytic sorting. The NK1R
traffics to ECE-1-containing endosomes. ECE-1
degrades SP in acidified endosomes, which
disrupts the SP/NK1R/b-arrestin/Src/MEKK and
ERK1/2 signalosome. (6) Slow recycling. The
NK1R then slowly recycles. (7) Resensitization.
Recycling mediates resensitization. (8) Down-
regulation. Chronic stimulation with SP stimulates
NK1R ubiquitination and lysosomal degradation.
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and bradykinin (Sturiale et al., 1999). Inhibitors of opioid-degrad-
ing peptidases have been developed as analgesics. A dual nepri-
lysin and neutral aminopeptidase N (EC 3.4.11.2) inhibitor has
anti-nociceptive actions in rodents that are mediated by opioids
in the periphery (Bonnard et al., 2015). These effects may be
largely attributable to inhibition of aminopeptidase N since a ne-
prilysin inhibitor would be expected to block degradation of alge-
sic peptides such as SP and bradykinin.
GPCR desensitization also terminates plasma membrane
signaling (Figure 5, step 1). GPCR kinases (GRKs) phosphorylate
activated receptors and thereby enhance their affinity forb-arrest-
ins, which interact with activated receptors and uncouple them
from G proteins. Disruption of these mechanisms interferes with
nociception, which illustrates their importance for pain transmis-
sion. Thus, b-arrestin-2 knockout mice exhibit exacerbated
morphine analgesia consistent with compromisedMOR desensi-Neuron 88, Ntization (Bohn et al., 1999). GRK2 hetero-
zygotic mice (50% reduction in GRK2)
exhibit sustained inflammatory pain, and
selective reduction of GRK2 in Nav1.8 no-
ciceptors exacerbates hyperalgesia via
enhanced sensitization of TRPV1 (Eijkel-
kamp et al., 2010). Given that GRK2 is
often downregulated in inflammatory con-
ditions, these studies suggest amajor role
for this kinase in regulating the severity
and duration of inflammatory pain.
8.2. Anchoring Proteins Organize
Painful Signals
Anchoring or scaffolding proteins lack
intrinsic enzymatic activity but interact
with and organize signaling partners into
functional units. In the context of noci-ception, anchoring proteins are critically important for GPCR-
dependent activation and sensitization of ion channels (reviewed
in Fischer and McNaughton, 2014).
A Kinase Anchoring Proteins (AKAPs) interact with GPCRs,
channels, kinases, phosphatases, GTPases, and phosphodies-
terase and can assemble signaling complexes in subcellular do-
mains that are necessary for nociception. Three N-terminal lipid
binding domains target AKAP79/150 tomembranes, where it as-
sembles an adenylyl cyclase, PKA, PKC, and TRPV1 complex
that facilitates bradykinin- and PGE2-evoked sensitization of
TRPV1 (Efendiev et al., 2013; Jeske et al., 2009; Zhang et al.,
2008). An understanding of the molecular basis of the interac-
tions between AKAP79/150 and TRP channels may enable the
development of drugs that disrupt these interactions and sup-
press pain. Peptides that block AKAP79/150 and TRPV1 interac-
tions suppress hyperalgesia, suggesting therapeutic potential
(Fischer et al., 2013).ovember 18, 2015 ª2015 Elsevier Inc. 643
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GPCRs, ion channels and signaling partners. In line with
their role in GPCR desensitization, b-arrestins can also desensi-
tize TRPV1. By recruiting phosphodiesterase 4D to TRPV1,
b-arrestin-2 suppresses cAMP levels and thereby restricts
PKA-dependent activation of TRPV1, which desensitizes the
channel (Por et al., 2013).
8.3. GPCR Trafficking through the Endosomal Network
Controls the Duration and Magnitude of Painful Signals
Activated GPCRs often traffic to endosomes, an extensive and
dynamic tubulo-vesicular network that extends throughout the
cytosol (Figure 5, steps 2–6). Agonist-evoked endocytosis has
been demonstrated for several GPCRs that regulate pain and
itch. Painful stimuli evoke NK1R endocytosis in second-order
neurons of rat spinal cord (Mantyh et al., 1995). Endogenous opi-
oids and drugs also stimulate endocytosis of MOR and DOR
throughout the nervous system (Faget et al., 2012; Poole et al.,
2011). However, there are marked differences in the ability of
some agonists to induce endocytosis of the same receptors.
Ligand-biased endocytosis is exemplified for MOR and DOR
and may explain the capacity of different ligands to evoke
tolerance to opioids. Whereas opioid peptides evoke MOR
endocytosis, morphine is usually unable to stimulate endocy-
tosis (Williams et al., 2013). Similarly, although enkephalin and
SNC80 strongly stimulate DOR endocytosis, ARM390 has a
limited capacity to stimulate DOR internalization (Pradhan
et al., 2010). After chronic administration of SNC80, DOR is
downregulated and mice exhibit SNC80 analgesic tolerance
that is presumably related to loss of cell-surface receptors. How-
ever, chronic administration of ARM390 does not lead to DOR
downregulation, although DOR signaling in nociceptive neurons
is compromised and mice demonstrate analgesic tolerance.
Thus, tolerance can occur by different mechanisms, which
depend on the agonist.
The molecular mechanisms of agonist-evoked endocytosis of
GPCRs have been extensively studied. By serving as adaptors
for clathrin and AP2, b-arrestins mediate endocytosis of many
GPCRs. Differences in the affinity of GPCRs for b-arrestins,
which depend on the extent of GRK-mediated phosphorylation
of intracellular domains (Oakley et al., 2000), can markedly affect
endocytosis. In instances where two or more receptors are
simultaneously activated in the samecell, a likely scenario in vivo,
competition for b-arrestins may underlie differences in receptor
trafficking. By virtue of high-affinity interactions, the NK1R se-
questers b-arrestins and impedes endocytosis and desensitiza-
tion of the NK3R (Schmidlin et al., 2002) and MOR (Yu et al.,
2009), which display lower-affinity interactions with b-arrestins.
The importance of b-arrestin sequestration for pain and itch re-
mains to be determined.
Internalized GPCRs either recycle or are degraded, depending
on the receptor and the conditions of stimulation. GPCR recy-
cling is often necessary for the sustained actions of extracellular
agonists. One determinant of the rate of recycling is GPCR affin-
ity for b-arrestins (Oakley et al., 1999). GPCRs that form low-af-
finity interactions with b-arrestins in endosomes (MOR, NK3R)
rapidly recycle and resensitize, whereas GPCRs that form
high-affinity interactions with b-arrestins in endosomes (NK1R)
recycle and resensitize slowly (Schmidlin et al., 2003). Ligand644 Neuron 88, November 18, 2015 ª2015 Elsevier Inc.degradation in endosomes also determines the rate of recycling.
Endothelin-converting enzyme-1 (ECE-1, EC 3.4.24.71) de-
grades SP and CGRP in early endosomes, which promotes
dissociation of signalosomes, allowing receptors, freed from
b-arrestins, to recycle and resensitize (Padilla et al., 2007; Roos-
terman et al., 2007) (Figure 5 step 5). ECE-1-dependent recycling
allows for sustained inflammatory signaling by SP (Cattaruzza
et al., 2009; Jensen et al., 2014). In a similar manner, ECE-2 de-
grades certain opioids in early endosomes to promote recycling
and resensitization of DOR (Gupta et al., 2014) and MOR (Gupta
et al., 2015). These pathways of GPCR recycling may be physi-
ologically regulated. Thus, SP activation of the NK1R in trigemi-
nal neurons promotes MOR recycling and resensitization by a
mechanism that involves PKC-mediated phosphorylation of
MOR (Bowman et al., 2015). SP enhances resensitization of fen-
tanyl-stimulated anti-nociception in mice, suggesting the exis-
tence of a physiologically relevant crosstalk between GPCRs
that mediate inflammatory pain (NK1R) and opioid analgesia
(MOR). However, recycling is not always required for resensitiza-
tion. A substantial proportion of activated NK1R remains at the
cell surface. b-arrestin-1 can recruit protein phosphatase 2A to
the non-internalizing receptor, where dephosphorylation medi-
ates resensitization (Murphy et al., 2011) (Figure 5, step 1).
Some activated GPCRs, including PAR2 and DOR, traffic
to lysosomes after degradation. The mechanisms of lysosomal
targeting of GPCRs are not fully understood and vary between
receptors. Lysosomal trafficking of PAR2 requires cCbl-medi-
ated ubiquitination (Jacob et al., 2005) followed by AMSH- and
UBPY-mediated deubiquitination in endosomes (Hasdemir
et al., 2009). The E3 ligase AIP4 ubiquitinates DOR, which then
undergoes AMSH- and UBPY-mediated deubiquitination (Hislop
et al., 2009). A cytoplasmic protein that can bind to the C termi-
nus of DOR, G protein-coupled receptor-associated protein
(GASP), also contributes to DOR downregulation (Whistler
et al., 2002). Sustained signaling by agonists of lysosome-tar-
geted GPCRs requires mobilization of stores of intact receptors
or new receptor synthesis, but the regulation of plasma mem-
brane trafficking of GPCR from stores has not been examined
in detail.
8.4. Endosomal Platforms for Sustained GPCR Signals
Originally considered merely a conduit for GPCR recycling or
degradation, endosomes are now viewed as a vital site of
signaling (Irannejad and von Zastrow, 2014; Murphy et al.,
2009) (Figure 5, step 3). By recruiting GPCRs and components
of the mitogen-activated protein kinase cascades to endo-
somes, b-arrestins can assemble signalosomes that define the
location and function of activated kinases (DeFea et al., 2000a,
2000b). By degrading SP and disrupting the SP, NK1R, b-ar-
restin, Src signalosome, ECE-1 terminates endosomally medi-
ated ERK1/2 activation (Cottrell et al., 2009; Jensen et al.,
2014). The traditional view of G protein-dependent plasmamem-
brane signaling and b-arrestin-dependent and G protein-inde-
pendent endosomal signaling has been blurred by the apprecia-
tion that someGPCRs can signal from endosomes via G proteins
(Calebiro et al., 2009; Irannejad et al., 2013). Very little is known
about the contribution of endosomal signaling to pain and itch.
However, given that painful stimuli can trigger GPCR endocy-
tosis, it is possible that endosomal signaling contributes to
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receptor in dorsal root ganglia neuronsmediates the pruritogenic
actions of endothelin-1 (Kido-Nakahara et al., 2014). Whether
endosomes are a platform for sustained nociceptive transmis-
sion remains to be determined.
9. Conclusions and Future Perspectives
The realization that GPCRs are dynamic signaling machines,
rather than static sentinels of signaling pathways, provides
new insights into their physiological functions and reveals novel
options for therapeutic intervention. The ability of receptors to
adopt distinct conformations upon association with different
agonists, signaling partners, or other receptors may explain allo-
steric modulation, biased agonism, and the functional conse-
quences of receptor oligomerization and constitutive activity.
The trafficking of activated receptors to microdomains of plasma
and endosomal membranes underlies the generation of signals
in subcellular compartments that may account for receptor-spe-
cific effects.
Despite important advances, our understanding of the confor-
mational and positional dynamism of GPCRs is incomplete.
Most information about the structure of GPCRs derives from
studies of antagonist-stabilized receptors. Although conforma-
tional changes are thought to explain allosteric modulation,
direct experimental evidence showing how binding of an allo-
steric ligand dynamically alters the conformation of the orthos-
teric binding site is mostly lacking. The structural basis of biased
agonism, by which different agonists are thought to induce
receptors to adopt distinct conformations and to couple to
divergent signaling pathways, is poorly understood. Similarly,
although some antagonist-bound GPCRs crystallize as dimers,
the impact of oligomerization on GPCR conformation and pre-
cisely how this affects function is not known. Mutational studies
have identified domains that are important for constitutive activ-
ity of GPCRs, but the structural basis of spontaneous activity is
uncertain. Agonist-stimulated trafficking of GPCRs within the
endosomal network has been extensively studied, although the
mechanisms by which receptors signal from endosomes, and
its importance for complex physiological and pathophysiological
processes, remains to be defined.
Our understanding of allosteric modulation, biased agonism,
oligomerization, constitutive activity, and compartmentalized
signaling largely derives from studies of GPCRs in artificial sys-
tems. There are major challenges to studying these processes
in functionally relevant cells, such as sensory neurons, and in
determining their importance for complex physiological and
pathophysiological processes, including pain and itch. The effi-
cacy of allosteric modulators in vivo is critically dependent on
the tone of the endogenous system, and the differential in vivo
actions of various agonists of the same receptor may be ex-
plained by altered stability and distribution, rather than biased
agonism. Even the apparently simple question of whether two
GPCRs are colocalized in membrane microdomains of the
same neuron, a prerequisite for their capacity to dimerize, is
fraught with controversy. Many GPCRs can become constitu-
tively active after mutation and when overexpressed in cell lines,
but the importance of constitutive activity in vivo is less certain.
Although it is well established that some GPCRs can robustlyinternalize in sensory neurons, the importance of this process
to pain and itch transmission is unknown, and whether targeting
GPCRs in endosomes is an effective therapeutic approach
remains to be investigated.
Despite these difficulties, there remains a deep interest in
signaling and trafficking of GPCRs. Future developments in our
understanding of the conformational and positional dynamism
of GPCRs will certainly provide further insights into the operation
of these complex signaling machines. The challenge will be to
translate these insights into an improved understanding of the
integrated and complex processes of pain and itch, and to use
this knowledge to inform the development of more selective
and effective therapies for these often intractable disorders.
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